Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III

被引:12
|
作者
Kern, David M. [1 ]
Balu, Sanjeev [2 ]
Tunceli, Ozgur [1 ]
Anzalone, Deborah [2 ]
机构
[1] HealthCore Inc, Wilmington, DE 19801 USA
[2] AstraZeneca Pharmaceut LP, Wilmington, DE USA
关键词
Adherence; Coronary heart disease; Dyslipidemia; Retrospective; Statins; MEDICATIONS; GUIDELINES; UPDATE;
D O I
10.1185/03007995.2014.971151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare clinical characteristics, statin treatment patterns and adherence among patients at different risk for coronary heart disease (CHD) as defined by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines. Methods: Patients >= 18 years old with >= 1 claim for dyslipidemia, >= 1 statin claim, or >= 1 LDL-C value >= 100 mg/dL were identified from 1 January 2007 to 31 July 2012. Patients were classified as low risk (LR) (0-1 risk factor: hypertension, age >= 45 years [men] or >= 55 years [women], or low HDL-C), moderate/moderately high risk (MR) (>= 2 risk factors), high risk (HR) (CHD or CHD risk equivalent), or very high risk (VHR) (acute coronary syndrome, or established cardiovascular disease plus diabetes or metabolic syndrome). Medication use and lipid levels during the 12 months before and statin use during the 6 months after index were compared across risk groups. Results: There were 1,524,351 LR, 242,357 MR, 188,222 HR, and 57,469 VHR patients identified. Statin use was observed in 15% of all patients, but was higher in the VHR group (45%) versus LR (12%), MR (18%), and HR (29%) groups. Simvastatin accounted for 50%-52% of all statin use, and average statin dose was higher among VHR patients compared with all other groups. Adherence was low overall (mean proportion of days covered [PDC]: 0.57), but higher among VHR (0.69) versus others (mean PDC: 0.55, 0.59, and 0.59 in LR, MR, and HR groups, respectively). Conclusions: Statin treatment was low across all risk groups, and VHR patients had higher doses and better adherence compared with other risk groups. However, adherence was not optimal, indicating a potential limited benefit from statin treatment.
引用
收藏
页码:2443 / 2451
页数:9
相关论文
共 50 条
  • [1] Risk analysis of coronary heart diseases in Korean adults by using The National Cholesterol Education Program Adult Treatment Panel III
    Lee, Yong-Wha
    Min, Won-Ki
    Lee, Woochang
    Chun, Sail
    Park, Hyosoon
    Lee, Do-Hoon
    Lee, You Kyoung
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2007, 21 (03) : 178 - 182
  • [2] National Cholesterol Education Program Adult Treatment Panel-III guidelines and the abolition of symptomatic coronary artery disease
    Silverstein, HR
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (05): : 654 - 654
  • [3] Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Cheng, Alice Y. Y.
    Leiter, Lawrence A.
    CURRENT OPINION IN CARDIOLOGY, 2006, 21 (04) : 400 - 404
  • [4] Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Grundy, SM
    Cleeman, JI
    Merz, CNB
    Brewer, HB
    Clark, LT
    Hunninghake, DB
    Pasternak, RC
    Smith, SC
    Stone, NJ
    CIRCULATION, 2004, 110 (02) : 227 - 239
  • [5] New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III
    Talbert, RL
    AMERICAN JOURNAL OF MANAGED CARE, 2002, 8 (12): : S301 - S307
  • [6] A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Grundy, SM
    Cleeman, JI
    Merz, CNB
    Brewer, HB
    Clark, LT
    Hunninghake, DB
    Pasternak, RC
    Smith, SC
    Stone, NJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (08) : 1329 - 1330
  • [7] Role of the National Cholesterol Education Program Adult Treatment Panel III guidelines in managing dyslipidemia
    Talbert, RL
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (13) : S3 - S8
  • [8] Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options
    Stone, NJ
    Bilek, S
    Rosenbaum, S
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (4A): : 53E - 59E
  • [9] Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: Getting to goal
    McKenney, JM
    PHARMACOTHERAPY, 2003, 23 (09): : 26S - 33S
  • [10] National Cholesterol Education Program Adult Treatment Panel III guidelines and obesity: Implications for Canada
    Ardern, CI
    Katzmarzyk, PT
    CANADIAN JOURNAL OF CARDIOLOGY, 2003, 19 (10) : 1171 - 1177